Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

@article{Gaede2003MultifactorialIA,
  title={Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.},
  author={Peter Haulund Gaede and Pernille Nygaard Vedel and Nicolai Larsen and Gunnar Vagn Hagemann Jensen and Hans-Henrik D. Parving and Oluf Pedersen},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 5},
  pages={
          383-93
        }
}
BACKGROUND Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke… 

Figures and Tables from this paper

Effect of a multifactorial intervention on mortality in type 2 diabetes.

In at-risk patients with type 2 diabetes, intensive intervention with multiple drug combinations and behavior modification had sustained beneficial effects with respect to vascular complications and on rates of death from any cause and from cardiovascular causes.

Blood pressure control, risk factors and cardiovascular prognosis in patients with diabetes: 30 years of progress.

  • J. MouradS. Le Jeune
  • Medicine
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension
  • 2008
The major coronary event risk remains high in type 2 diabetes patients, and the results of the ADVANCE trial provided a step forward in treatment, with intensive glycaemic and blood pressure control reduced the risk of vascular events.

Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study

Multifactorial target treatment in patients with short-duration type 2 diabetes can effectively reduce the risk of macrovascular complications, and simultaneous target control of systolic blood pressure and fasting plasma glucose reduced therisk of atherosclerosis plaques.

A Multifactorial Approach in Type 2 Diabetes Over 3 Years Decelerates Progression of Subclinical Arterial Disease in Routine Clinical Practice

The beneficial effect of multifactorial treatment of cardiovascular (CV) risk factors (RFs) in type 2 diabetes (T2D) is well established from randomized clinical trials. We prospectively evaluated

Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.

A substantial rise in T2DM incidence in the community and an increase in the incidence of myocardial infarction (MI) in patients with T1DM are suggested, suggesting it is important to manage effectively the increased vascular risk of diabetic patients.

Therapy and clinical trials: glycaemia and prevention of macroangiopathy in type 2 diabetes.

It was found that patients receiving intensive therapy had a significantly lower risk of CVD (hazard ratio 0.47; 95% CI, 0.24–0.73; P1⁄4 0.008) compared with the conventionally treated group over the 7.8 years of follow-up.

Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Nephropathy in Diabetes type 2 study induces a remarkable benefit on the risk of MACEs and mortality in high-risk DKD patients.
...

References

SHOWING 1-10 OF 23 REFERENCES

Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.

Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing major CVD events, cerebral and cardiac, in both non-insulin-treated diabetic and nondiabetic older patients with ISH, with few adverse effects.

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.

Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

It is suggested that cholesterol lowering with simvastatin improves the prognosis of diabetic patients with CHD and the absolute clinical benefit achieved by cholesterol lowering may be greater in diabetic than in nondiabetic patients withCHD because diabetic patients have a higher absolute risk of recurrent CHD events and other atherosclerotic events.

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus, which are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density cholesterol, raised blood pressure, hyperglycaemia, and smoking.

A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women.

It is shown that maturity-onset clinical diabetes is a strong determinant of coronary heart disease, ischemic stroke, and cardiovascular mortality among middle-aged women and the adverse effect of diabetes is amplified in the presence of other cardiovascular risk factors.

GEMFIBROZIL FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MEN WITH LOW LEVELS OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL

Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level, suggesting that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.

Diabetes and decline in heart disease mortality in US adults.

The smaller declines in mortality for diabetic subjects in the present study indicate that these changes may have been less effective for people with diabetes, particularly women.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.